Table 2.
Characteristics of myelofibrosis patients.
| Number of patients | 39 |
| Age (years), median [IQR] | 71 [64.75] |
| Sex (male), n (%) | 23 (59) |
| Secondary myelofibrosis, n (%) | 9 (23) |
| Post-polycythemia vera, n | 7 |
| Post-essential thrombocythemia, n | 2 |
| Time since diagnosis (years), median [IQR] | 3.95 [0.97.9.96] |
| Treatment | |
| Ruxolitinib, n (%) | 21 (54) |
| Interferon 2α, n (%) | 3 (8) |
| Hydroxyurea, n (%) | 2 (5) |
| Prednisone, n (%) | 1 (3) |
| Darbepoetinα, n (%) | 24 (62) |
| Hemoglobin (g/dL), median [IQR] | 6.7 [6.2, 7.5] |
| White blood cell count (x 109/l), median [IQR] | 8.1 [4.7, 12.6] |
| Neutrophil count (x 109/l), median [IQR] | 4.6 [2.7, 9.1] |
| Platelet count (x 109/l), median [IQR] | 211 [112, 269] |
| Lactate dehydrogenase (U/l), median [IQR] | 440 [341, 650] |
| Transfusion dependent, n (%) | 9 (23) |
| Mutation, n (%) | |
| CALR | 5 (13) |
| JAK2V617F | 28 (72) |
| Double-negative | 4 (10) |
| Unknown | 2 (5) |
| JAK2V617F allele burden, median [IQR] | 57.5 [30.8.75.0] |
| Hypertension, n (%) | 12 (30) |
| Type 2 diabetes mellitus, n (%) | 4 (10) |
| Thromboembolic events, n (%) | 5 (13) |
| 8-oxodG (nmol/mmol creatinine), median [IQR] | 3.21 [2.06, 5.21] |
| 8-oxoGuo (nmol/mmol creatinine), median [IQR] | 4.86 [3.17, 9.30] |
8-oxodG, 8-oxo-7,8-dihydro-2′-deoxyguanosine; 8-oxoGuo, 8-oxo-7,8-dihydroguanosine.